Brett Myrter is a seasoned Finance Professional with 17 years of extensive experience at top-tier organizations, including Biogen, Genentech, and Intel. Currently serving as the Director of Business Planning Finance for Pharma Operations & Technology at Biogen, Brett plays a pivotal role in aligning financial...
Brett Myrter is a seasoned Finance Professional with 17 years of extensive experience at top-tier organizations, including Biogen, Genentech, and Intel. Currently serving as the Director of Business Planning Finance for Pharma Operations & Technology at Biogen, Brett plays a pivotal role in aligning financial strategies with the company’s mission to improve patient outcomes through innovative therapies. His expertise is particularly evident in his capacity as the Site Finance Lead for the Solothurn Manufacturing Plant, where he oversees financial operations and ensures robust financial planning and analysis (FP&A) that supports manufacturing efficiency and cost-effectiveness.
Brett's role as a Finance Business Partner for Product Technology Development and Asset Development involves close collaboration with cross-functional teams to drive strategic initiatives and optimize resource allocation. His proficiency in SAP and Essbase enhances his ability to manage complex budgets and financial models, ensuring that Biogen's projects are not only financially viable but also aligned with the company’s long-term goals. With a strong focus on internal controls and acquisition integration, Brett has successfully navigated the financial landscapes of various projects, contributing to the seamless execution of Biogen’s portfolio management strategies.
Over the past decade, Brett has cultivated a deep understanding of the pharmaceutical industry, leveraging his skills in managerial finance, pricing strategies, and cross-functional team leadership to deliver insights that empower decision-making. His commitment to excellence and passion for finance have made him an invaluable asset to Biogen, as he continues to drive financial performance and support the development of groundbreaking therapies that transform patient lives.
